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Background: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first
agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have
linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class,
carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We
report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with
refractory multiple myeloma.
Case presentation: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had
been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants.
After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock
and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L).
Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse
of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension,
and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with
thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension
improved. Due to progression of multiple myeloma, he died a few months later.
Conclusion: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the
temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms
after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident
renal thrombotic microangiopathy in our patient.
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Because impairment of kidney function in patients with
multiple myeloma (MM) can be caused by a variety of
conditions, ascertaining the etiology of kidney dysfunction
in patients with MM represents a challenging task for the
practicing nephrologist. Patients with MM are at risk of ac-
quiring acute kidney injury (AKI) as a result of light chain
cast nephropathy [1], hypercalcemia [2], bisphosphonate-
induced tubular injury [3] and lenalidomide nephrotoxicity
[4]. Similarly, syndromes of glomerular involvement can* Correspondence: liliane.hobeika@louisville.edu
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unless otherwise stated.also occur in MM as a result of light or heavy chain
deposition disease, amyloidosis or bisphosphonate-induced
podocytopathy. Furthermore, patients with MM who un-
dergo hematopoietic stem cell transplantation (HSCT) are
also at risk of acquiring renal syndromes inherent to
HSCT, such as ischemic acute tubular necrosis and
thrombotic microangiopathy (TMA) [5,6]. The clinical
features of TMA syndromes include microangiopathic
hemolytic anemia, thrombocytopenia, and organ injury.
The pathological features are vascular damage manifested
by arteriolar and capillary thrombosis with characteristic
abnormalities in the endothelium and vessel wall. Renal
pathology in TMA is characterized by thickened capillary
walls, occlusion of vascular lumens, fibrin depositionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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dothelial zone.
Over the last few years, multiple reports have unveiled
an association between anti-angiogenic therapy and TMA.
Antineoplastic drugs designed to target vascular endo-
thelial growth factor (VEGF) such as sunitinib, sorafenib,
bevacizumab, and others, have been linked to the develop-
ment of a syndrome characterized by severe hypertension
and/or acute or chronic kidney injury, with or without
proteinuria, and associated with histopathological evi-
dence of TMA in the kidney [7,8]. Bortezomib is a prote-
asome inhibitor that was approved by the Food and Drug
Administration (FDA) in 2003 for the treatment of refrac-
tory MM and subsequently in 2008 as an initial treatment
of patients with MM. Although it does not target VEGF
directly, bortezomib has also been reported to be associ-
ated with TMA. In July 2012, a new member in its class,
carfilzomib, was approved by the FDA for the treatment
of relapsing or refractory MM.
In this report, we summarize the case of a patient with
MM status post autologous HSCT and chronic kidney dis-
ease who experienced worsening hypertension along with
a substantial increase in proteinuria shortly after the initi-
ation of carfilzomib for the treatment of refractory disease.
We propose carfilzomib as a possible trigger of malignant
hypertension and renal TMA in this case.
Case presentation
The patient was a 62 year-old Caucasian man with a
long-standing history of essential hypertension and a 4-
year history of MM (IgG kappa subtype). The latter was
diagnosed after suffering a T7 compression fracture. At
that time, his kidney function was normal (serum cre-
atinine: 0.9 mg/dL (79.56 μmol/L)) and his blood pres-
sure was fairly well controlled on four agents (carvedilol
extended-release 80 mg daily, diltiazem 60 mg three
times daily, valsartan 320 mg daily and hydralazine
25 mg three times daily). As initial therapy for MM, he
received melphalan for conditioning, four cycles of lena-
lidomide and dexamethasone, followed by autologous
HSCT. Three months later, his kidney function remained
within normal limits. He subsequently developed a few
episodes of volume depletion associated with transient
increases in serum creatinine level, after which his
serum creatinine stabilized at a level of 1.4 mg/dL
(123.76 μmol/L). Ten months after HSCT, he was started
on bortezomib, cyclophosphamide and dexamethasone
(VCD) due to progression of MM. He received five cycles
of VCD. His blood pressure remained fairly well con-
trolled with no changes to his anti-hypertensive regimen.
Fifteen months after the first HSCT and 1 month after
completing VCD, he underwent a second autologous
HSCT for relapse. This time, the hospital course was com-
plicated with septic shock and a severe bout of AKI, withserum creatinine peaking at 7.4 mg/dL (654.16 μmol/L).
After requiring four weeks of acute hemodialysis, he
partially regained kidney function, ultimately being dis-
charged from the hospital with a new baseline serum
creatinine of 2.1 mg/dL (185.64 μmol/L). At the time of
discharge, his antihypertensive regimen was modified to
avoid blockade of the renin-angiotensin system in the
setting of AKI. Accordingly, he was switched to hydral-
azine 50 mg three times daily, diltiazem extended-release
360 mg daily, metoprolol 200 mg twice daily and a cloni-
dine patch 0.3 mg/24 h.
Seventeen months after the second HSCT, a follow-up
bone marrow biopsy specimen revealed persistent plasma
cell infiltration. As a result, he was initiated on carfilzomib
(20 mg/m2; followed by 27 mg/m2, four weeks apart), thal-
idomide 100 mg daily and dexamethasone 20 mg per
week. Six weeks after the initiation of chemotherapy, the
patient developed abrupt worsening of lower extremity
edema and his hypertension became more difficult to
control. After being stable with four agents (hydralazine,
diltiazem, metoprolol and clonidine) averaging a blood
pressure of 142/74 mmHg during previous office visits,
he presented with a blood pressure of 206/100 mmHg
(Figure 1). His physical examination also revealed pallor,
but otherwise no additional abnormalities. Laboratory
data showed: hemoglobin 8.2 g/dL (5.09 μmol/L), plate-
let count 53 K/cumm, serum creatinine 2.1 mg/dL
(185.64 μmol/L), lactate dehydrogenase 183 IU/L, hapto-
globin 23 mg/dL (0.23 g/L), total bilirubin 0.6 mg/dL
(10.26 μmol/L), C3 112.3 mg/dL (1.123 g/L) (normal
range: 88–201 mg/dL), C4 54.4 mg/dL (0.544 g/L) (nor-
mal range: 16–47 mg/dL), albumin 2.8 g/dL (28 g/L),
serum kappa free light chain 82.4 mg/dL (normal range:
0.33-1.94), serum lambda free light chain 0.69 mg/dL
(normal range: 0.57-2.63), serum free kappa/lambda ratio
119.42 (normal range: 0.26-1.65). Urinalysis showed
300 mg/dL protein on dipstick but no hematuria or
pyuria. Urine protein electrophoresis showed elevated
kappa light chain in the gamma zone at 11.9 mg/dL
(232 mg per 24 hours) and a 24-hour urine collection
revealed 2.6 grams of protein (53.3% albumin). Previous
testing had shown presence of low-grade proteinuria
(less than 0.5 grams per day) (Table 1). In addition to
his antihypertensives, he was also taking acyclovir, cita-
lopram, esomeprazole, zolpidem, tramadol and aspirin.
He required the addition of eplerenone 25 mg daily, ni-
fedipine extended-release 90 mg daily and benazepril
30 mg daily, for a total of 7 antihypertensives. Despite
the 7-drug combination, he remained hypertensive aver-
aging 190/95 mmHg.
A renal sonogram revealed a right kidney of 10.8 and a
left kidney of 10.6 cm of longitudinal diameter with mod-
erately increased cortical echogenicity. Following acute re-






































Figure 1 Schematic illustrating the clinical and laboratory presentation of our patient. Proteinuria in month 5 was measured on a spot
urine sample. Proteinuria in months 6 and 8 was estimated from a 24-hour urine collection. Black arrows reflect carfilzomib administration
(20 mg/m2 in month 4, and 27 mg/m2 in month 5).
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formed to evaluate the newly developed overt proteinuria.
Histological examination of the biopsy specimen on light
microscopy disclosed 8 out of 17 globally sclerotic glom-
eruli, some mesangiolysis (Figure 2a), moderate interstitial
fibrosis and tubular atrophy, and severe arteriolar hyalino-
sis. There was no evidence of myeloma cast nephropathy.
No thrombi were identified in the glomerular capillaries
or arterioles. Congo red stain was negative. Immunofluor-
escence showed 4 out of 14 glomeruli with global sclerosis
and one small artery that stained intensely for fibrin
(Figure 2b), C1q, IgM and C3. The corresponding H&E-
stained cryosection showed a thrombus in that artery.
The specimen was negative for linear deposition of IgG
or kappa along the glomerular and tubular basement
membranes. Electron microscopy of one glomerulus
showed diffuse foot process effacement, endothelial cellTable 1 Laboratory values
Variable (normal range) 2 months prior to biopsy
Hemoglobin (14–18 g/dL) 8.8
Platelets (140–440 k/cumm) 75
Serum Creatinine (0.6-1.3 mg/dL) 2.1
LDH (100–240 IU/L) NA
Haptoglobin (36–195 mg/dL) NA
Serum M-spike (g/dL) 1.06
Proteinuria (0–0.3 g/day) 0.33
albumin on UPEP (%) NA
M-spike on UPEP (%) NA
Abbreviations: LDH, lactate dehydrogenase; NA, not available; UPEP, urine protein eswelling and some loops with flocculent material be-
tween the endothelial cell and the glomerular basement
membrane (Figure 2c). There was no immune complex
deposition or finely granular electron dense deposits
along the glomerular or tubular basement membranes.
In summary, the findings were consistent with TMA,
glomerular podocytopathy, hypertensive-related injury
and chronic scarring.
After the results of the kidney biopsy were reviewed
and discussed, carfilzomib was discontinued. Eight weeks
later, proteinuria slightly improved to 1 gram on a 24 hour
urine collection. His serum creatinine remained stable at
1.7 mg/dL (150.28 μmol/L) at that time. His arterial blood
pressure improved significantly averaging 135/75 mmHg
on 5 agents. Due to progression of MM and a joint deci-
sion of not pursuing further treatment, the patient died













Figure 2 Renal histologic findings in the patient. a. Light microscopy: mesangiolysis on Jones’ methenamine silver stain. b. Immunofluorescence:
Small artery intensely stained for fibrin. c. Electron microscopy: Endothelial cell swelling and flocculent material between endothelial cell and
glomerular basement membrane.
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We present a case of an individual who experienced
abrupt worsening of hypertension and proteinuria 6 weeks
after receiving carfilzomib for the treatment of refractory
MM. A kidney biopsy specimen revealed a TMA lesion
along with podocytopathy and evidence of chronic scar-
ring. No previous report of renal TMA associated with
carfilzomib was found in published literature. Applying
the Naranjo criteria for adverse drug reactions [9], the
present case meets the criteria of ‘possible’ association
with TMA. First, the timing of the administration of the
drug and the subsequent clinical syndrome support our
contention. The onset of worsening hypertension and pro-
teinuria coincided with the initiation of carfilzomib, as
depicted in Figure 1. Secondly, there is a precedent of re-
ports of a drug of a similar class being associated with
TMA. Thirdly, the patient partially recovered after the
drug was discontinued.
Renal TMA is a known complication of HSCT that typ-
ically occurs approximately 3 months post-transplantation
(range 14 – 240 days) [10]. Notably, it is much more likely
to occur after allogeneic compared to autologous HSCT,
occurring in 8-12% following allogeneic HSCT. Although
factors inherent to HSCT, such as graft-versus-host dis-
ease, high-dose chemotherapy, and total body irradiation
have been implicated in the pathogenesis of allogeneic
HSCT-associated renal TMA, it is generally thought
that the use of calcineurin inhibitors (CI) may largely
explain the increased incidence of renal TMA [5,6] afterallogeneic HSCT given the well-described association
between CIs and TMA in solid organ transplantation
[11]. On the other hand, TMA associated with autolo-
gous HSCT is extremely rare, only case reports were
found in the literature [12-14]. In our case, the second
autologous HSCT was performed more than a year
prior to the onset of worsening proteinuria and malig-
nant hypertension. Therefore, the type of HSCT, the ab-
sence of CI therapy and the timing of the clinical
presentation do not favor autologous HSCT as the pri-
mary etiology of renal TMA in our patient. Radiation
therapy was not given in this case.
The development of overt proteinuria along with un-
controlled hypertension stimulated the clinical decision
to perform a kidney biopsy. In addition to the TMA le-
sion, the biopsy specimen revealed evidence of podocy-
topathy in the form of diffuse foot process effacement,
thereby explaining the proteinuric nature of the renal
syndrome. Various degrees of focal or diffuse foot
process effacement were reported in all the patients in-
cluded in a case series describing the association of
TMA and chemotherapy with monoclonal antibodies
against vascular endothelial growth factor (VEGF) [8].
We identified 4 cases of bortezomib-associated TMA
in the medical literature. Two of those reports described
cases of patients with MM who developed microangio-
pathic hemolytic anemia and thrombocytopenia during
the course of the first cycle of bortezomib [15,16].
ADAMTS13 activity was normal in both cases. The
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itional reports described cases of microangiopathic
hemolytic anemia and thrombocytopenia complicated
with AKI [17,18]. Although kidney biopsy was not
performed, a renal TMA lesion was suspected. In
addition to drug discontinuation, those patients under-
went plasmapheresis.
Bortezomib is a dipeptide boronate 20S proteasome
inhibitor. It inhibits nuclear factor kappa B (NF-KB)
translocation/transcription activity by blocking the deg-
radation of its inhibitor iKB. Inhibition of NF-KB leads
to a decrease in VEGF transcription [19]. Production of
VEGF by podocytes is indispensable for maintenance of
the adjacent glomerular endothelium. Anti-VEGF che-
moagents, such as bevacizumab and sorafenib, can cause
TMA by direct microvascular toxicity initiated by endo-
thelial injury [8,20,21]. Bortezomib can also inhibit IL-6
induced proliferation and angiogenesis and enhance the
release of pro-inflammatory cytokines (IL-6 and TNF-
alpha) and generation of cell mediated immune response
[22]. In addition, it has been shown that VEGF, acting
through VEGFR-2, activates endothelial nitric oxide syn-
thase (eNOS) activity, leading to increased vasodilatory
nitric oxide production. Anti-VEGF therapies might
cause systemic deficiency of nitric oxide with consequent
hypertension [23,24]. Therefore, it has been speculated
that the mechanism by which proteasome inhibitors
may induce TMA also involve modulation of VEGF.
Notably, although bortezomib is being increasingly used
to treat antibody-mediated rejection in organ transplant-
ation, no reports of associated TMA have emerged to
date [25-27]. Therefore, the strength of the association
requires further validation.
Carfilzomib is a tetrapeptide epoxyketone proteasome
inhibitor. In preclinical studies, carfilzomib showed
greater selectivity than bortezomib for the proteasome
and had anti-proliferative activity in cells resistant to
bortezomib [28]. In view of the previously reported asso-
ciation of bortezomib with TMA [15-18], we speculate
that carfilzomib could have been involved in the patho-
genesis of renal TMA in our case. In contrast to previ-
ous reports of proteasome inhibitor-associated TMA
[15-18], our case describes a patient who presented with
overt proteinuria and worsening hypertension but with-
out extrarenal features of microangiopathic hemolytic
anemia, i.e., renal-limited TMA. Undoubtedly, it could
be argued that the long-standing history of essential
hypertension could be responsible of some of the histo-
logical findings in the kidney biopsy specimen knowing
that the renal TMA lesion in our patient is similar to that
of malignant hypertension. Nonetheless, we hypothesize
that the abruptness of the clinical presentation may reflect
the onset of a mechanism of injury induced by carfilzo-
mib, triggering malignant hypertension in a patient whowas perhaps at high risk of developing it due to his under-
lying essential hypertension.
Conclusions
In summary, we suggest that clinicians should be aware
of the possibility of an association between exposure to
carfilzomib and the development of a clinical syndrome
characterized by worsening proteinuria and uncontrolled
HTN and pathological evidence of renal TMA. Discon-
tinuation of the drug should be considered only after
careful evaluation of risks and benefits of the chemo-
therapy and the prognosis of the existing malignancy.
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